Research Funding

Current funding:

• NIH R01 138931 (MPI: Upchurch/Sharma) ‘Pannexin signaling in abdominal aortic aneurysms’

• James and Esther King Biomedical Research Program (MPI: Upchurch/Sharma) ‘Role of myeloid-derived suppressor cells in aortic aneurysms and rupture’

• NIH R01 148019 (MPI: Jiang/Upchurch) ‘Role of RNA-mediated danger signals in regulating TAAD development’

• NIH RO1 HL081629 (PI) ‘Gender differences in experimental aortic aneurysms’

• NIH RO1 HL124131 (PI) ‘Role of neutrophil extracellular traps in AAA pathogenesis’

Expected funding:

• NIH RO1 153341 (MPI: Upchurch/Sharma) Novel specialized pro-resolving lipid mediators in resolution of aortic aneurysms and rupture

Completed funding:

• 2013- 2018 NIH Co-Investigator, Reuse of ZD4054 for patients with symptomatic PAD

• 2014-2017 AHA Scientist Development Grant, Mentor, Role of KLF2 in aortic aneurysm formation

• 2011 – 2014 Astra Zeneca, Pl: G.U. Novel systemic targets to inhibit experimental aneurysm formation.

• 2009-2013 NIH (RO1), PI: G.U. Gender differences in aortic aneurysm

• 2007-2012 NIH (RO1), PI: G.U. Gender differences in aortic aneurysm

• 2001-2006 NIH (KO8), PI: G.U. Mentored Clinical Scientist Development Award

• 2001-2006 PI: G.U. Lifeline Foundation® Research Award